← Human Trials & Peer-Reviewed Studies
Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism
Plain-language guide to PMID 8914034 (1996): clinical trial study of Parathyroid Hormone (PTH 1-84) in 2 patients, hyperparathyroidism.
Key Facts
- PMID
- 8914034
- Journal
- Kidney international
- Year
- 1996
- Study type
- Clinical Trial
- Authors
- Indridason OS et al. (5 authors)
- DOI
- 10.1038/ki.1996.483
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a clinical trial.
To determine the relative importance of parathyroid gland enlargement and alterations in calcium sensing (set-point changes) in the pathogenesis of uremic secondary hyperparathyroidism (2 degrees HPT), the researchers investigated the relationship between estimates of parathyroid gland size and calcium-mediated parathyroid hormone (PTH) suppression in 19 normocalcemic 2 degrees HPT patients on chronic maintenance hemodialysis.
Why It Was Studied
The researchers compared their results to calcium-mediated PTH suppression in 12 normal volunteers, 12 patients with familial benign hypocalciuric hypercalcemia (FBHH), a disorder of abnormal calcium sensing, and 9 subjects with primary hyperparathyroidism (1 degree HPT), which is characterized by both calcium set-point abnormalities and parathyroid gland enlargement.
Who Took Part
The abstract describes 2 patients taking part.
What Was Measured
The researchers compared their results to calcium-mediated PTH suppression in 12 normal volunteers, 12 patients with familial benign hypocalciuric hypercalcemia (FBHH), a disorder of abnormal calcium sensing, and 9 subjects with primary hyperparathyroidism (1 degree HPT), which is characterized by both calcium set-point abnormalities and parathyroid gland enlargement.
PubMed files the paper under topics including Calcium, Hyperparathyroidism, Secondary, Parathyroid Glands, Parathyroid Hormone, Regression Analysis, Renal Dialysis and Uremia.
What This Means in Plain Language
This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 2 patients in people with hyperparathyroidism.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1996 (Kidney international), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.